The invention relates to a dry powder inhalation (DPI) formulation and a process for its preparation. The dry powder inhalation formulation comprises micronized favipiravir/Ivermectin, first lactose, second lactose, and optionally at least one excipient. The dry powder formulation of this patent increases the bioavailability of the Favipiravir/Ivermectin, patient compliance, and reduced adverse effects.
Patent Status: Granted
Stage: Industrial stage
The inventor is open for licensing or assignment
